| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemodynamic therapy (CDT) is an emerging cancer treatment strategy that leverages the unique tumor microenvironment to generate toxic reactive oxygen species (ROS) in situ. Unlike conventional chemotherapy, which often has systemic toxicity, CDT aims to induce localized cell death through chemical reactions that occur preferentially within tumors. How Chemodynamic Therapy Works 1.Tumor Microenvironment Exploitation: Tumors often exhibit a higher concentration of hydrogen peroxide (H₂O₂), an acidic environment, and elevated levels of certain metal ions (e.g., Fe²⁺). CDT exploits these characteristics to trigger chemical reactions selectively within the tumor. 2.Fenton and Fenton-like Reactions: At the heart of CDT is the Fenton reaction, where transition metal ions (typically iron) catalyze the decomposition of H₂O₂ to generate hydroxyl radicals (•OH). These radicals are highly reactive and induce oxidative damage to cellular components like lipids, proteins, and DNA. The basic Fenton reaction: Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻ 3.Minimizing Systemic Toxicity: Because the reaction heavily depends on the tumor’s specific conditions (e.g., acidic pH and high H₂O₂ levels), CDT can achieve a localized therapeutic effect with reduced harm to healthy tissues. 4.Nanomaterials as Catalysts: Often, CDT is facilitated by nanoparticle catalysts (e.g., iron oxide, copper-based, or other metal-based nanoparticles) that can be engineered to accumulate in tumor tissues. These nanomaterials not only provide a catalytic surface but can also be modified for improved tumor targeting and controlled release. Chemodynamic therapy provides a promising approach for cancer treatment by using the tumor’s inherent properties—like high H₂O₂ and acidic pH—to catalyze ROS generation via Fenton reactions. By targeting pathways related to oxidative stress, iron metabolism, redox balance, and cell survival signaling, CDT aims to selectively induce cancer cell death while reducing collateral damage to normal tissues. Target Pathways in Chemodynamic Therapy Oxidative Stress Pathways:ROS Generation, Mitochondrial Dysfunction, MMP, DNA Damage Iron Homeostasis and Metabolism: Fenton Reaction Catalysis: The availability of Fe²⁺ is crucial for the Fenton reaction, making the iron uptake pathways a critical target. MAPK/ERK Pathway, PI3K/Akt Pathway: increased ROS can inhibit pro-survival pathways like PI3K/Akt, tipping the balance towards cell death. Glutathione (GSH) Depletion: Nrf2 Pathway Inhibition: Inhibiting Nrf2 can make cancer cells more susceptible to ROS. Acidic Tumor Microenvironment: Many nanomaterials used in CDT are designed to be activated in acidic conditions, ensuring that the Fenton reaction proceeds efficiently within the tumor milieu. Autophagic: Increased ROS levels can also affect autophagy—a cellular “self-eating” process Chemodynamic therapy — Chemodynamic therapy is a tumor-microenvironment-activated anticancer modality that uses transition-metal catalysts, usually delivered as nanomaterials or metal-containing platforms, to convert endogenous hydrogen peroxide into highly cytotoxic radical species through Fenton or Fenton-like chemistry. It is best classified as a redox-based nanotherapeutic and oxidative-stress amplification strategy rather than a single drug. The standard abbreviation is CDT. Its conceptual origin is tumor-selective exploitation of relatively higher intratumoral H₂O₂, acidic or mildly acidic compartments, and abnormal redox buffering, often with iron, copper, manganese, cobalt, or related catalytic systems. In practice, modern CDT is usually formulated as a combination platform that also depletes glutathione, perturbs ferroptosis control, relieves hypoxia for partner modalities, or couples with chemo-, photo-, sono-, radio-, or immunotherapy. Current oncology use remains largely experimental and formulation-dependent rather than standardized clinical practice. Primary mechanisms (ranked):
Bioavailability / PK relevance: CDT is delivery-constrained. Most clinically relevant constructs are nanoparticles, metal-organic frameworks, or catalytic nanoplatforms whose efficacy depends on tumor deposition, metal release, intratumoral retention, catalytic accessibility, and eventual clearance. PK is therefore platform-specific rather than modality-wide. Reticuloendothelial uptake, liver/spleen sequestration, incomplete tumor penetration, and long-term metal or carrier biocompatibility remain central translational constraints. In-vitro vs systemic exposure relevance: CDT is not primarily a fixed systemic concentration modality; it is a local catalytic process that depends on H₂O₂ availability, acidity, redox buffering, and catalyst localization. Many in-vitro studies likely overstate efficiency because cell systems often provide more favorable catalyst contact, higher effective dosing, or simplified redox conditions than heterogeneous in-vivo tumors. A major translational issue is that endogenous tumor H₂O₂ and acidity are often insufficient for robust Fenton chemistry unless the platform also boosts H₂O₂ production, depletes GSH, adds heat, or combines with another modality. Clinical evidence status: Predominantly preclinical. The field is supported by extensive mechanistic and animal literature, with growing translational interest and at least early first-in-human activity reported for an iron-loaded carbon nanoparticle platform in advanced solid tumors, but CDT is not an established standard oncology treatment and no specific CDT platform appears to have broad regulatory approval as a named cancer therapy at present. Chemodynamic Therapy Mechanistic Axes
P: 0–30 min |
| Source: |
| Type: |
| Cuproptosis is a recently described form of regulated cell death that is distinct from other types such as apoptosis, necroptosis, and pyroptosis. It is primarily characterized by its direct dependence on copper and its interaction with mitochondrial processes. -Cuproptosis begins with the intracellular accumulation of copper. This free copper binds directly to lipoylated proteins, which are enzymes involved in important mitochondrial metabolic processes such as the tricarboxylic acid (TCA) cycle. -Protein Aggregation: The binding of copper to these lipoylated proteins induces their aggregation. This aggregation disrupts normal protein functions and compromises mitochondrial integrity. Cuproptosis represents a unique form of regulated cell death driven by the accumulation of copper and its consequent interactions with mitochondrial lipoylated proteins. |
| 1596- | Cu, | CDT, | Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:280 Target#:1139 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid